C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
Surgical resection is the preferred way to treat solid cancer tumors. But even if the tumor is completely removed, stray cancer cells may still be shedding tumor DNA into the blood, allowing cancer regrowth and disease recurrence. Despite close monitoring with serum markers and imaging tests, detection is usually delayed until months to years after recurrence. By then, it might be too late to apply even the most effective remedies.
50%
Bladder
40%
Lung
30%
Melanoma
20%
Colorectal
C2i’s liquid biopsy is a robust tool for cancer tumor monitoring. It is the first to work by identifying subtle changes in genetic patterns across the entire tumor. Based on advanced bioinformatics and AI, it compares thousands of data points obtained from periodic liquid biopsy blood tests of a patient to her own baseline of sequenced tumor tissue and whole genome analysis. The unique pattern generated is converted to a cancer burden score, making cancer more predictable and manageable.
C2i’s Whole Genome analysis solution for monitoring tumor
recurrence in post-resection cancer patients shows significant benefits
100X more sensitive
Tests more than 100X sensitive than any other monitoring alternative
Unique pattern analysis
Ultra sensitive by analyzing thousands of reference points rather than a single point
Only 2ml need
Proprietary technology shows results in blood volumes as little as 2ml
Cloud-based
Offered as a diagnostic service at the point-of-care enabling rapid deployment worldwide
C2i was formally established in 2019 and is based on technology developed at Cornell.
We are backed by private investors, and currently have 10 employees in our offices in the US and Israel.
Management
Advisory Board
Dr. Asaf Zviran
CEO & CSO
Asaf Zviran, Ph.D
CEO & CSO
Asaf brings 15+ years of R&D management in biology and defense.To date he has managed to publish 13 papers with over 1,700 citations (including Nature and Stem Cell). Asaf received multiple awards and grants. He is an IDF R&D Officer (Captain) with a PhD in Molecular Biology